Patterns of Reproductive hormones and Metabolic biomarkers During Perimenopause in Owerri Populations
Keywords:
Perimenopause, Estradiol, FSH, LH, Biomarkers, OwerriAbstract
Perimenopause is a transitory phase preceding menopause, marked by significant hormonal fluctuations and physiological adjustments. This study examines the trends of reproductive hormones and metabolic indicators in perimenopausal women living in Owerri, Nigeria. A cross-sectional analytical investigation was performed on 100 women aged 40–55 years, divided into early and late perimenopausal cohorts. Blood samples were examined for follicle-stimulating hormone (FSH), luteinizing hormone (LH), oestradiol (E₂), progesterone, prolactin, and some metabolic indicators, including lipid profile. The findings indicated notable elevations in FSH and LH levels, accompanied by a reduction in oestradiol and progesterone concentrations during the perimenopausal phases (p < 0.05). Biomarkers of lipid metabolism (total cholesterol, LDL-C) were raised in late perimenopausal women, indicating heightened cardiometabolic risk. These results highlight the relationship between hormonal fluctuations and metabolic biomarker changes during perimenopause in African women. Regular testing of endocrine and metabolic markers is advised for the prompt identification of perimenopausal diseases.
References
1. Taylor, S., & Davis, S. R. (2025). Is it time to revisit the recommendations for initiation of menopausal hormone therapy? The Lancet Diabetes & Endocrinology, 13(1), 69–74.
2. Burger, H. G., Hale, G. E., Robertson, D. M., & Dennerstein, L. (2007). A review of hormonal changes during the menopausal transition: Focus on findings from the Melbourne Women’s Midlife Health Project. Human Reproduction Update, 13(6), 559–565.
3. Adeli, K., Higgins, V., & Bohn, M. K. (2023). Reference information for the clinical laboratory. In N. Rifai, R. W. K. Chiu, I. Young, C. A. D. Burnham, & C. T. Wittwer (Eds.), Tietz textbook of clinical chemistry and molecular diagnostics (7th ed., pp. 1390–1470). St. Louis, MO: Elsevier.
4. Seifer, D. B., MacLaughlin, D. T., Christian, B. P., Feng, B., & Shelden, R. M. (2002). Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertility and Sterility, 77(3), 468–471.
5. Matthews, K. A., Kuller, L. H., Sutton-Tyrrell, K., Chang, Y. F., & Edmundowicz, D. (2009). Changes in cardiovascular risk factors during the perimenopause and postmenopause. Annals of Epidemiology, 19(7), 481–488.
6. Motlani, V., Motlani, G., Pamnani, S., Sahu, A., & Acharya, N. (2023). Endocrine changes in postmenopausal women: A comprehensive view. Cureus, 15(12), e51287.
7. Ambikairajah, A., Tabatabaei-Jafari, H., Walsh, E., Hornberger, M., & Cherbuin, N. (2020). Longitudinal changes in fat mass and the hippocampus. Obesity, 28, 1263–1269.
8. de Kat, A. C., Broekmans, F. J. M., & Lambalk, C. B. (2021). Role of AMH in prediction of menopause. Frontiers in Endocrinology, 12, 733731.
9. Moolhuijsen, L. M. E., & Visser, J. A. (2020). Anti-Müllerian hormone and ovarian reserve: Update on assessing ovarian function. Journal of Clinical Endocrinology & Metabolism, 105, 3361–3373.
10. Ambikairajah, A., Walsh, E., & Cherbuin, N. (2022). A review of menopause nomenclature. Reproductive Health, 9, 29.
11. Laven, J. S. E. (2022). Early menopause results from instead of causes premature general ageing. Reproductive Biomedicine Online, 45, 421–424.
12. McNeil, M. A., & Merriam, S. B. (2021). Menopause. Annals of Internal Medicine, 174(7), 97–112.
13. Broekmans, F. J., Kwee, J., Hendriks, D. J., Mol, B. W., & Lambalk, C. B. (2006). A systematic review of tests predicting ovarian reserve and IVF outcome. Human Reproduction Update, 12, 685–718.
14. Nelson, S. M., Davis, S. R., Kalantaridou, S., Lumsden, M. A., Panay, N., & Anderson, R. A. (2023). Anti-Müllerian hormone for the diagnosis and prediction of menopause: A systematic review. Human Reproduction Update, 29(3), 327–346.
15. Nerenz, R. D., & Boha, B. (2023). Reproductive endocrinology and related disorders. In N. Rifai, R. W. K. Chiu, I. Young, C. A. D. Burnham, & C. T. Wittwer (Eds.), Tietz textbook of clinical chemistry and molecular diagnostics (7th ed., pp. 846–884). St. Louis, MO: Elsevier.
16. Ramezani Tehrani, F., Bidhendi Yarandi, R., Solaymani-Dodaran, M., Tohidi, M., Firouzi, F., & Azizi, F. (2020). Improving prediction of age at menopause using multiple anti-Müllerian hormone measurements: The Tehran Lipid-Glucose Study. Journal of Clinical Endocrinology & Metabolism, 105,
17. Messinis, I. E., Messini, C. I., & Dafopoulos, K. (2014). Novel aspects of the endocrinology of the menstrual cycle. Reproductive Biomedicine Online, 28(6), 714–722.
18. Ambikairajah, A., Tabatabaei-Jafari, H., Hornberger, M., & Cherbuin, N. (2021). Age, menstruation history, and the brain. Menopause, 28, 167–174.
19. Crandall, C. J., Mehta, J. M., & Manson, J. E. (2023). Management of menopausal symptoms: A review. JAMA, 329, 405–420.
20. Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology & Metabolism, 97, 1159–1168.
21. Laven, J. S. E. (2020). Genetics of menopause and primary ovarian insufficiency: Time for a paradigm shift? Seminars in Reproductive Medicine, 38, 256–262.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Nwanguma Eberechi, Ibanga Etim Imoh, Uzodinma Udeoha, Ikem Amarachi Promise, Nnodim Johnkennedy (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
